Clinical Trial: Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07479797) titled 'Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy' on March 13.

Brief Summary: The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory large B-cell lymphoma (LBCL) after one prior line of therapy.

The primary objective of this study is to evaluate the efficacy of KITE-753 versus axicabtagene ciloleucel.

Study Start Date: Aug., 2026

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Large B-cell Lymphom...